HIV type 1 lipopeptide vaccine
includes 6 lipopeptides (N1-3, G1-2, E); well tolerated and able to induce a specific CD4(+) and CD8(+) T cell responses; in clinical trials phase II 7/2006
Also Known As:
anti-HIV type 1 lipopeptide vaccine
Networked: 0
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results